Effects of Post-Session Supplemental Hydromorphone on Opioid Addiction: Detroit

nuke

Bluelighter
Joined
Nov 7, 2004
Messages
4,191
Effects of Post-Session Supplemental Hydromorphone on Drug Seeking Behavior in Opioid Dependent Individuals

Drug dependence is often characterized by severe drug seeking behavior. Learning to understand, predict, and control this maladaptive choice behavior may lead to improved prevention and treatment strategies. HYD is a drug that is currently used as a cough suppressant and to relieve pain. The purpose of this study is to determine the extent to which opioid drug seeking behavior by heroin dependent individuals can be reduced by environmental factors, including supplemental opioid drug availability, drug price, and alternative non-drug reinforcers. Specifically, this study will determine whether knowledge of post-session HYD availability influences drug seeking behavior in heroin dependent individuals, who are maintained on buprenorphine during their participation.

Participants in this observational study will take part in multiple trials in which they have the opportunity to choose either HYD or money. On the first two experimental days, prior to choice sessions, participants will receive a sample of the drug doses that can be chosen, 12 and 24 mg of HYD. During test sessions, participants will have 12 opportunities to choose either drug or money. Participants will use a computer to earn choices. Respiration rate, oxygen saturation, heart rate, and blood pressure will be monitored throughout choice trials. Supplemental HYD will be made available following some choice sessions. Self-report questionnaires will be completed at different times during the study. Participants will be maintained on buprenorphine throughout the study, with a minimum 2-week lead before the experiment, and a fixed 3-week detoxification after study completion.

http://www.clinicaltrials.gov/ct/show/NCT00218361

Inclusion Criteria:
18 Years-55 Years, Genders Eligible for Study: Both
Opioid dependent, as determined by the structured clinical interview for DSM-IV (SCID) and Addiction Severity Index (ASI)
Positive urine test for opiates
Willing to use an adequate form of contraception for the duration of the study
Reads and writes English

Exclusion Criteria:
Psychiatric illness, as determined by the DSM-IV criteria
History of or current neurological disease, including structural abnormalities, seizures, infection, peripheral neuropathy, and head traumas
History of cardiovascular disease, myocardial infarction, chest pain, or edema
Systolic blood pressure greater than 160 mm Hg or less than 95 mm Hg; PR diastolic blood pressure greater than 95 mm Hg
Pulmonary disease, including obstructive pulmonary disease, cor pulmonale, tuberculosis, and asthma
Systemic disease (e.g., endocrinopathies, liver or kidney failure, myxedema, hypothyroidism, Addison's disease, autoimmune disease)
Current alcohol or sedative drug dependence
Pregnant or breastfeeding
Currently receiving treatment for opioid dependence
Known phobia of injections

Started August 2005; currently in progress and accepting new participants.

Contact
Please refer to this study by ClinicalTrials.gov identifier NCT00218361

Lisa Sulkowski 313-993-3966

United States, Michigan
Wayne State University, Detroit, Michigan, 48207, United States; Recruiting
Mark Greenwald, PhD 313-993-3965

Study chairs or principal investigators

Mark Greenwald, PhD, Principal Investigator, Wayne State University

(Please do not PM me in regards to this, I am not affiliated with this research)
 
Last edited by a moderator:
I don't think so, actually. Here's the author's page: http://www.med.wayne.edu/psychiatry/SARD/greenwald.htm

2003-2007 "Pharmacological Studies of Opioid Dependence in Humans" (Mark Greenwald, Project PI, 15% effort), NIH/NIDA P50 DA00254, clinical research component of Center Grant to Univ. of Michigan titled, “Narcotic Drug and Opioid Peptide Basic Research” (James Woods, Center Director). Purpose: Determine methadone's duration of action on mu-receptor binding potential, plasma methadone and saliva cortisol levels; spontaneous opioid withdrawal symptoms, and the ability of methadone to attenuate effects of hydromorphone; and whether opioid dependence alters impulsive drug preference, using delayed discounting procedures. Funding period: July 1, 2003-June 30, 2007. Total direct costs (subcontract): $398,221. Year 4 direct costs: $100,000.

Maybe he can't find someone to publish it.
 
It's probably just not ready yet or we haven't had a good look in pubmed to find it :)

It's frustrating but once you write a journal article (and that takes effort), you submit, they (hopefully) accept with revisions, you revise, they (hopefully) accept revised version, and then you wait up to years for it to be published. A somewhat lengthy process which I wish were shorter, but I guess it does mean not just anybody with a tale to tell can be published in peer reviewed journals.
 
Top